Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial (2019)

Peer-Reviewed Study · Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabaté A, Coulidiaty AGV, Rouamba N, Dabiré RK · April 13, 2019

Foy BD et al., 2019-04-13: Cluster-randomized trial in eight villages in Burkina Faso in which five additional three-weekly ivermectin doses cut cumulative childhood malaria episodes by about 20% with no significant excess of adverse events.

Frequently repeated mass administrations of ivermectin during the malaria transmission season can reduce malaria episodes among children without significantly increasing harms in the populace.

Foy BD et al., 2019-04-13: Cluster-randomized trial in eight villages in Burkina Faso in which five additional three-weekly ivermectin doses cut cumulative childhood malaria episodes by about 20% with no significant excess of adverse events. Single-blind (outcomes assessor), parallel-assignment, two-arm cluster-randomized trial; 8 villages (4 per arm), 2712 participants, 590 children aged 5 or younger in the active-detection cohort; Burkina Faso; 2015 rainy season. All participants received ivermectin 150-200 micrograms/kg plus albendazole 400 mg; the intervention arm received five further ivermectin doses at 3-week intervals over 18 weeks. Comparator: single MDA plus albendazole. Result: 2.00 vs 2.49 episodes per child (risk difference -0.49, 95% CI -0.79 to -0.21, p=0.0009). Adverse events 45 (3%) vs 24 (2%), risk ratio 1.63 (1.01-2.67), p=0.060. Funded by the Bill & Melinda Gates Foundation. NCT02509481. Grant listed: UL1 TR001863 (NIH/NCATS). Study type: randomized trial.